KR20060066729A - 우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합 - Google Patents
우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합 Download PDFInfo
- Publication number
- KR20060066729A KR20060066729A KR1020067003210A KR20067003210A KR20060066729A KR 20060066729 A KR20060066729 A KR 20060066729A KR 1020067003210 A KR1020067003210 A KR 1020067003210A KR 20067003210 A KR20067003210 A KR 20067003210A KR 20060066729 A KR20060066729 A KR 20060066729A
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- propyl
- methyl
- chloro
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003772 serotonin uptake inhibitor Substances 0.000 title claims abstract description 85
- 238000011282 treatment Methods 0.000 title claims abstract description 24
- 239000003112 inhibitor Substances 0.000 title claims description 30
- 208000020401 Depressive disease Diseases 0.000 title description 4
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 title description 3
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 title description 3
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims abstract description 54
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- 229940123454 Glucose transporter 1 inhibitor Drugs 0.000 claims abstract description 40
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 37
- 208000019022 Mood disease Diseases 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 208000035475 disorder Diseases 0.000 claims abstract description 17
- 230000036506 anxiety Effects 0.000 claims abstract description 13
- 208000032841 Bulimia Diseases 0.000 claims abstract description 12
- 206010006550 Bulimia nervosa Diseases 0.000 claims abstract description 12
- 208000028698 Cognitive impairment Diseases 0.000 claims abstract description 11
- 208000030990 Impulse-control disease Diseases 0.000 claims abstract description 11
- 208000008589 Obesity Diseases 0.000 claims abstract description 11
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims abstract description 11
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract description 11
- 206010041250 Social phobia Diseases 0.000 claims abstract description 11
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims abstract description 11
- 208000026345 acute stress disease Diseases 0.000 claims abstract description 11
- 208000022531 anorexia Diseases 0.000 claims abstract description 11
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 11
- 206010061428 decreased appetite Diseases 0.000 claims abstract description 11
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 11
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 10
- 206010013654 Drug abuse Diseases 0.000 claims abstract description 10
- 235000020824 obesity Nutrition 0.000 claims abstract description 10
- 208000030814 Eating disease Diseases 0.000 claims abstract description 7
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract description 7
- 235000014632 disordered eating Nutrition 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 206010027951 Mood swings Diseases 0.000 claims abstract 4
- -1 villazodone Chemical compound 0.000 claims description 79
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 29
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 28
- 239000004480 active ingredient Substances 0.000 claims description 23
- 239000004471 Glycine Substances 0.000 claims description 20
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 20
- 239000002552 dosage form Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 11
- 229960001653 citalopram Drugs 0.000 claims description 11
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 229960002464 fluoxetine Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 229960004801 imipramine Drugs 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 6
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 6
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 6
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 6
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 6
- 229960002866 duloxetine Drugs 0.000 claims description 6
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 6
- 229960004341 escitalopram Drugs 0.000 claims description 6
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 6
- 229960004038 fluvoxamine Drugs 0.000 claims description 6
- 229960002296 paroxetine Drugs 0.000 claims description 6
- 229960002073 sertraline Drugs 0.000 claims description 6
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 6
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 5
- 229960004606 clomipramine Drugs 0.000 claims description 5
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims description 5
- 229960005217 dapoxetine Drugs 0.000 claims description 5
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 5
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims description 5
- 229960001800 nefazodone Drugs 0.000 claims description 5
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 5
- 229960004688 venlafaxine Drugs 0.000 claims description 5
- CDVLPBUKUVKVBA-UEDXYCIISA-N (2s)-2-[3-[5-chloro-1-(4-chlorophenyl)-2,3-dihydroinden-1-yl]propyl-methylamino]propanoic acid Chemical compound C1CC2=CC(Cl)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 CDVLPBUKUVKVBA-UEDXYCIISA-N 0.000 claims description 4
- BYEFBPYBYKBWFR-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 BYEFBPYBYKBWFR-UHFFFAOYSA-N 0.000 claims description 4
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 4
- YERIVNORZKQTBA-UHFFFAOYSA-N 2-[3-[5-chloro-1-(4-chlorophenyl)-2,3-dihydroinden-1-yl]propyl-methylamino]acetic acid Chemical compound C1CC2=CC(Cl)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 YERIVNORZKQTBA-UHFFFAOYSA-N 0.000 claims description 3
- KEIDEHNAVGKQCB-NVHKAFQKSA-N (2s)-2-[3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)propyl-methylamino]propanoic acid Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 KEIDEHNAVGKQCB-NVHKAFQKSA-N 0.000 claims description 2
- BQJWQOOWJOBXGB-ZDGMYTEDSA-N (2s)-2-[3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(F)C=C1 BQJWQOOWJOBXGB-ZDGMYTEDSA-N 0.000 claims description 2
- UAUWLEHSOZBEQW-YXWRBFHGSA-N (2s)-2-[3-[1-(4-fluorophenyl)-5-(trifluoromethyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound O1CC2=CC(C(F)(F)F)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(F)C=C1 UAUWLEHSOZBEQW-YXWRBFHGSA-N 0.000 claims description 2
- BLRLFAJWSBAXFC-YXWRBFHGSA-N (2s)-2-[3-[5-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound O1CC2=CC(Cl)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 BLRLFAJWSBAXFC-YXWRBFHGSA-N 0.000 claims description 2
- QNZUEKRUUYXCNU-GZWBLTSWSA-N (2s)-2-[3-[5-cyano-1-(4-cyanophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(C#N)C=C1 QNZUEKRUUYXCNU-GZWBLTSWSA-N 0.000 claims description 2
- KKNQZVJEWPHXIG-LBOXEOMUSA-N (2s)-2-[methyl-[3-(1-phenylinden-1-yl)propyl]amino]propanoic acid Chemical compound C1=CC2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 KKNQZVJEWPHXIG-LBOXEOMUSA-N 0.000 claims description 2
- BDLPQYZTXBBTQE-YPHUNTSASA-N (2s)-2-[methyl-[3-(3-methyl-1-phenyl-3h-2-benzofuran-1-yl)propyl]amino]propanoic acid Chemical compound O1C(C)C2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 BDLPQYZTXBBTQE-YPHUNTSASA-N 0.000 claims description 2
- DPSWTYBTRIJUIQ-CQSZACIVSA-N 2-[(2r)-4-[5-chloro-2-(3-methoxyphenyl)sulfanylphenyl]-2-methylpiperazin-1-yl]acetic acid Chemical compound COC1=CC=CC(SC=2C(=CC(Cl)=CC=2)N2C[C@@H](C)N(CC(O)=O)CC2)=C1 DPSWTYBTRIJUIQ-CQSZACIVSA-N 0.000 claims description 2
- XKOQVRLECUULHT-UHFFFAOYSA-N 2-[2-[1-(4-chlorophenyl)-3,3-dimethyl-2-benzofuran-1-yl]ethyl-methylamino]acetic acid Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 XKOQVRLECUULHT-UHFFFAOYSA-N 0.000 claims description 2
- CIWXIAJJCJIWOE-UHFFFAOYSA-N 2-[2-[1-(4-chlorophenyl)-5-(5-chlorothiophen-2-yl)-3h-2-benzofuran-1-yl]ethyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(Cl)S1 CIWXIAJJCJIWOE-UHFFFAOYSA-N 0.000 claims description 2
- SCTGAEHVEUYYGU-UHFFFAOYSA-N 2-[2-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]ethyl-methylamino]acetic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCN(C)CC(O)=O)C1=CC=C(F)C=C1 SCTGAEHVEUYYGU-UHFFFAOYSA-N 0.000 claims description 2
- HOKCJTQMQWEJBK-UHFFFAOYSA-N 2-[3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)propyl-methylamino]acetic acid Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC=C1 HOKCJTQMQWEJBK-UHFFFAOYSA-N 0.000 claims description 2
- MMEFKIFIMMDSTF-UHFFFAOYSA-N 2-[3-(5-chloro-1-thiophen-2-yl-3h-2-benzofuran-1-yl)propyl-methylamino]acetic acid Chemical compound O1CC2=CC(Cl)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CS1 MMEFKIFIMMDSTF-UHFFFAOYSA-N 0.000 claims description 2
- RQHGELJFTUQRGZ-UHFFFAOYSA-N 2-[3-(5-chloro-1-thiophen-2-yl-3h-2-benzofuran-1-yl)propyl-methylamino]butanoic acid Chemical compound O1CC2=CC(Cl)=CC=C2C1(CCCN(C)C(CC)C(O)=O)C1=CC=CS1 RQHGELJFTUQRGZ-UHFFFAOYSA-N 0.000 claims description 2
- SHIGDERHWRPXFW-UHFFFAOYSA-N 2-[3-[1,5-bis(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(Cl)C=C1 SHIGDERHWRPXFW-UHFFFAOYSA-N 0.000 claims description 2
- SQWYCLPSDYACTO-UHFFFAOYSA-N 2-[3-[1-(3-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC(Cl)=C1 SQWYCLPSDYACTO-UHFFFAOYSA-N 0.000 claims description 2
- PIUPRVAVNBKRAQ-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(2-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=CC=C1C PIUPRVAVNBKRAQ-UHFFFAOYSA-N 0.000 claims description 2
- OUFAHQPFGFOCCL-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=CC(C)=C1 OUFAHQPFGFOCCL-UHFFFAOYSA-N 0.000 claims description 2
- OEEPPXCUYXQRLI-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C2C(C=3C=CC(Cl)=CC=3)(CCCN(C)CC(O)=O)OCC2=C1 OEEPPXCUYXQRLI-UHFFFAOYSA-N 0.000 claims description 2
- RBAQCYGDDPOWCE-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(4-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(C)C=C1 RBAQCYGDDPOWCE-UHFFFAOYSA-N 0.000 claims description 2
- KAPQYVCDDXBUIY-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-[2-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=CC=C1C(F)(F)F KAPQYVCDDXBUIY-UHFFFAOYSA-N 0.000 claims description 2
- TXGJKJXYOREALM-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-[3-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=CC(C(F)(F)F)=C1 TXGJKJXYOREALM-UHFFFAOYSA-N 0.000 claims description 2
- JUWVFZAPYCYAKO-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-[4-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(C(F)(F)F)C=C1 JUWVFZAPYCYAKO-UHFFFAOYSA-N 0.000 claims description 2
- LTSWUMKWZXTGOB-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-fluoro-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(F)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 LTSWUMKWZXTGOB-UHFFFAOYSA-N 0.000 claims description 2
- ZLOHYHCNWKILRP-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-3,3-dimethyl-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 ZLOHYHCNWKILRP-UHFFFAOYSA-N 0.000 claims description 2
- BKZQAANJGUQRNB-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 BKZQAANJGUQRNB-UHFFFAOYSA-N 0.000 claims description 2
- HPGIDFCZZZSUNU-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-5-(trifluoromethyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(C(F)(F)F)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 HPGIDFCZZZSUNU-UHFFFAOYSA-N 0.000 claims description 2
- RTWGCBZBZKLFHN-UHFFFAOYSA-N 2-[3-[4-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC(C(=CC=C2)Cl)=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 RTWGCBZBZKLFHN-UHFFFAOYSA-N 0.000 claims description 2
- KDETUNZZDAVRHR-UHFFFAOYSA-N 2-[3-[4-chloro-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC(C(=CC=C2)Cl)=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 KDETUNZZDAVRHR-UHFFFAOYSA-N 0.000 claims description 2
- PFUNWACYBDHFAL-UHFFFAOYSA-N 2-[3-[5-bromo-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(Br)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 PFUNWACYBDHFAL-UHFFFAOYSA-N 0.000 claims description 2
- CYKZSTVLKQCCOE-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 CYKZSTVLKQCCOE-UHFFFAOYSA-N 0.000 claims description 2
- ZFKXLIIUEFDRBB-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC=C(C#N)C=C2CO1 ZFKXLIIUEFDRBB-UHFFFAOYSA-N 0.000 claims description 2
- USZSGVSBDOXSIJ-UHFFFAOYSA-N 2-[3-[5-fluoro-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC=C(F)C=C2CO1 USZSGVSBDOXSIJ-UHFFFAOYSA-N 0.000 claims description 2
- BQAUJJODONZZMO-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 BQAUJJODONZZMO-UHFFFAOYSA-N 0.000 claims description 2
- JVQZDCZIFSRDQU-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 JVQZDCZIFSRDQU-UHFFFAOYSA-N 0.000 claims description 2
- FQMHYNZGTKQLBE-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC(Cl)=CC=C2CO1 FQMHYNZGTKQLBE-UHFFFAOYSA-N 0.000 claims description 2
- FPZVLWDUJCYRDE-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(C)C=C1 FPZVLWDUJCYRDE-UHFFFAOYSA-N 0.000 claims description 2
- AWUMSKBXSBFQDV-UHFFFAOYSA-N 2-[4-[2-(4-propan-2-ylphenyl)sulfanylphenyl]piperazin-1-yl]acetic acid Chemical compound C1=CC(C(C)C)=CC=C1SC1=CC=CC=C1N1CCN(CC(O)=O)CC1 AWUMSKBXSBFQDV-UHFFFAOYSA-N 0.000 claims description 2
- YETJSWJHLRHFIV-UHFFFAOYSA-N 2-[4-[5-chloro-2-(4-methoxyphenyl)sulfanylphenyl]-2,2-dimethylpiperazin-1-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1SC1=CC=C(Cl)C=C1N1CC(C)(C)N(CC(O)=O)CC1 YETJSWJHLRHFIV-UHFFFAOYSA-N 0.000 claims description 2
- CEETWSDATDRVAC-UHFFFAOYSA-N 2-[methyl-[3-(3-methyl-1-phenyl-3h-2-benzofuran-1-yl)propyl]amino]butanoic acid Chemical compound O1C(C)C2=CC=CC=C2C1(CCCN(C)C(CC)C(O)=O)C1=CC=CC=C1 CEETWSDATDRVAC-UHFFFAOYSA-N 0.000 claims description 2
- GXOOUMOOGHJCHS-UHFFFAOYSA-N 2-[methyl-[3-(3-methyl-1-phenylinden-1-yl)propyl]amino]acetic acid Chemical compound C1=C(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC=C1 GXOOUMOOGHJCHS-UHFFFAOYSA-N 0.000 claims description 2
- HYHCUOXXBRKVIT-UHFFFAOYSA-N 2-[methyl-[3-[1-(4-methylphenyl)-3h-2-benzofuran-1-yl]propyl]amino]acetic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(C)C=C1 HYHCUOXXBRKVIT-UHFFFAOYSA-N 0.000 claims description 2
- FWMFQNAGGJQHLP-UHFFFAOYSA-N 2-[methyl-[3-[1-[3-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl]amino]acetic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC(C(F)(F)F)=C1 FWMFQNAGGJQHLP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- OSVAYUPHKDNSKR-UHFFFAOYSA-N ethyl 2-[3-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetate Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(=O)OCC)C1=CC=C(F)C=C1 OSVAYUPHKDNSKR-UHFFFAOYSA-N 0.000 claims description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- 206010029897 Obsessive thoughts Diseases 0.000 claims 1
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 claims 1
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000003001 depressive effect Effects 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract description 4
- 230000035882 stress Effects 0.000 abstract description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 62
- 241000700159 Rattus Species 0.000 description 12
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 10
- 229940076279 serotonin Drugs 0.000 description 10
- 238000001690 micro-dialysis Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 8
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 6
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000011260 co-administration Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000000697 serotonin reuptake Effects 0.000 description 5
- FDORQEIHOKEJNX-UHFFFAOYSA-N 2-[[3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid Chemical compound C=1C=C(F)C=CC=1C(CCN(C)CC(O)=O)OC(C=C1)=CC=C1C1=CC=CC=C1 FDORQEIHOKEJNX-UHFFFAOYSA-N 0.000 description 4
- 102000007527 Autoreceptors Human genes 0.000 description 4
- 108010071131 Autoreceptors Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 230000008517 inhibition of serotonin uptake Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000013275 serotonin uptake Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000003568 synaptosome Anatomy 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AQFYBBOVSHVEKK-CPFIQGLUSA-N (2s)-2-[3-[1-(4-chlorophenyl)-3,3-diethyl-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound C12=CC=CC=C2C(CC)(CC)OC1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 AQFYBBOVSHVEKK-CPFIQGLUSA-N 0.000 description 2
- XFPJZGUGGRESHD-PHJLCXHGSA-N (6r,10br)-6-(2-chlorophenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline;hydrobromide Chemical compound Br.ClC1=CC=CC=C1[C@H]1C2=CC=CC=C2[C@H]2CCCN2C1 XFPJZGUGGRESHD-PHJLCXHGSA-N 0.000 description 2
- PBALTVQMQFVDBV-GRTNUQQKSA-N (6s,10br)-6-(4-methylsulfanylphenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline;perchloric acid Chemical compound OCl(=O)(=O)=O.C1=CC(SC)=CC=C1[C@H]1C2=CC=CC=C2[C@H]2CCCN2C1 PBALTVQMQFVDBV-GRTNUQQKSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WETRBJOSGIDJHQ-UHFFFAOYSA-N 2-(3,4-dihydronaphthalen-2-ylmethyl)-4,5-dihydro-1h-imidazole Chemical compound C=1C2=CC=CC=C2CCC=1CC1=NCCN1 WETRBJOSGIDJHQ-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- OFCNTYBPPAQCRE-UHFFFAOYSA-N 3-(2-aminoethyl)-3h-indol-5-ol Chemical compound C1=C(O)C=C2C(CCN)C=NC2=C1 OFCNTYBPPAQCRE-UHFFFAOYSA-N 0.000 description 2
- 0 C=*1*CCNCC1 Chemical compound C=*1*CCNCC1 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 229940088352 Glycine transporter inhibitor Drugs 0.000 description 2
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- FZSPJBYOKQPKCD-VIFPVBQESA-N [1-(4-chlorophenyl)-2-methylpropan-2-yl] (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-VIFPVBQESA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229960003225 alaproclate Drugs 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229960002980 amitriptyline oxide Drugs 0.000 description 2
- ZPMKQFOGINQDAM-UHFFFAOYSA-N amitriptylinoxide Chemical compound C1CC2=CC=CC=C2C(=CCC[N+](C)([O-])C)C2=CC=CC=C21 ZPMKQFOGINQDAM-UHFFFAOYSA-N 0.000 description 2
- 229960002519 amoxapine Drugs 0.000 description 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 229960004333 indeloxazine Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 229950001527 nitroxazepine Drugs 0.000 description 2
- CGYWLLGTCBIGSR-UHFFFAOYSA-N nitroxazepine Chemical compound O=C1N(CCCN(C)C)C2=CC=CC=C2OC2=CC=C([N+]([O-])=O)C=C21 CGYWLLGTCBIGSR-UHFFFAOYSA-N 0.000 description 2
- FTKXWCQSVJPWPZ-VDWBQBBKSA-N org 6906 Chemical compound Cl.C1C2=CC=CC=C2[C@H]2C=C[C@@H](N)[C@@H]1C2 FTKXWCQSVJPWPZ-VDWBQBBKSA-N 0.000 description 2
- AVVSOBGTJTTZKQ-RXVWUEJASA-N org 6997 Chemical compound Cl.C1C2=CC(Cl)=CC=C2[C@H]2C=C[C@@H](N)[C@@H]1C2 AVVSOBGTJTTZKQ-RXVWUEJASA-N 0.000 description 2
- LWRJZIPAGMGXQJ-DIJVWCDGSA-N org-6582 Chemical compound Cl.C1C2=CC(Cl)=CC=C2[C@@H]2[C@@H](N)[C@H]1C=CC2 LWRJZIPAGMGXQJ-DIJVWCDGSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- BNKIWXODDDABSJ-UHFFFAOYSA-N tiflucarbine Chemical compound N1C2=CC(F)=C3SC=C(C)C3=C2C2=C1CCN(CC)C2 BNKIWXODDDABSJ-UHFFFAOYSA-N 0.000 description 2
- 229950008817 tiflucarbine Drugs 0.000 description 2
- 229960003991 trazodone Drugs 0.000 description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
- 229960002431 trimipramine Drugs 0.000 description 2
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 2
- 210000005111 ventral hippocampus Anatomy 0.000 description 2
- RLMHMDMIOFCETG-UBDBMELISA-N (2s)-2-[3-(3,3-diethyl-1-phenyl-2-benzofuran-1-yl)propyl-methylamino]propanoic acid Chemical compound C12=CC=CC=C2C(CC)(CC)OC1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 RLMHMDMIOFCETG-UBDBMELISA-N 0.000 description 1
- TUKYQPWIBZTOSR-BJQOMGFOSA-N (2s)-2-[methyl-[3-(1-phenyl-3h-2-benzothiophen-1-yl)propyl]amino]propanoic acid Chemical compound S1CC2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 TUKYQPWIBZTOSR-BJQOMGFOSA-N 0.000 description 1
- WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 1
- RXLKHTMQOSDEFY-CQSZACIVSA-N 2-[(2r)-4-[5-chloro-2-(4-methoxyphenyl)sulfanylphenyl]-2-methylpiperazin-1-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1SC1=CC=C(Cl)C=C1N1C[C@@H](C)N(CC(O)=O)CC1 RXLKHTMQOSDEFY-CQSZACIVSA-N 0.000 description 1
- FVJLOLWSOFHASD-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-3,3-diethyl-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C12=CC=CC=C2C(CC)(CC)OC1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 FVJLOLWSOFHASD-UHFFFAOYSA-N 0.000 description 1
- KGPQQENJOWEIII-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-3,3-dimethyl-2h-inden-1-yl]propyl-methylamino]acetic acid Chemical compound C1C(C)(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 KGPQQENJOWEIII-UHFFFAOYSA-N 0.000 description 1
- UFGTZUKOBHLAAC-UHFFFAOYSA-N 4-(5,6-dimethyl-1-benzofuran-2-yl)piperidine Chemical compound O1C=2C=C(C)C(C)=CC=2C=C1C1CCNCC1 UFGTZUKOBHLAAC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 101710164184 Synaptic vesicular amine transporter Proteins 0.000 description 1
- 102100034333 Synaptic vesicular amine transporter Human genes 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000002934 adrenergic neuron Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960000584 citalopram hydrobromide Drugs 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940052827 glytone Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- AKRQHOWXVSDJEF-UHFFFAOYSA-N heptane-1-sulfonic acid Chemical compound CCCCCCCS(O)(=O)=O AKRQHOWXVSDJEF-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- SVFXPTLYMIXFRX-BBRMVZONSA-N indatraline Chemical compound C1([C@@H]2C[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 SVFXPTLYMIXFRX-BBRMVZONSA-N 0.000 description 1
- 229950008889 indatraline Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- ASNYPHGOFQAGQM-UHFFFAOYSA-N n,n-dimethyl-5-(4-nitrophenoxy)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-7-amine Chemical compound C1C(N(C)C)CCC2=CC=CC=C2C1OC1=CC=C([N+]([O-])=O)C=C1 ASNYPHGOFQAGQM-UHFFFAOYSA-N 0.000 description 1
- QXLNAYIFEMXTDZ-UHFFFAOYSA-N n-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-[2-methyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]benzamide Chemical compound C1=C(N2CCN(C)CC2)C(OC)=CC=C1NC(=O)C(C=C1)=CC=C1C(C(=C1)C)=CC=C1C1=NN=C(C)O1 QXLNAYIFEMXTDZ-UHFFFAOYSA-N 0.000 description 1
- 229950000323 napamezole Drugs 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- HGEYJZMMUGWEOT-UHFFFAOYSA-N roxindole Chemical compound C12=CC(O)=CC=C2NC=C1CCCCN(CC=1)CCC=1C1=CC=CC=C1 HGEYJZMMUGWEOT-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000003727 serotonin 1A antagonist Substances 0.000 description 1
- 239000004000 serotonin 1B antagonist Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49673803P | 2003-08-21 | 2003-08-21 | |
| DKPA200301198 | 2003-08-21 | ||
| DKPA200301198 | 2003-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060066729A true KR20060066729A (ko) | 2006-06-16 |
Family
ID=34219531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067003210A Withdrawn KR20060066729A (ko) | 2003-08-21 | 2004-08-18 | 우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060223857A1 (enExample) |
| EP (1) | EP1660130A1 (enExample) |
| JP (1) | JP2007502785A (enExample) |
| KR (1) | KR20060066729A (enExample) |
| CN (1) | CN1867358A (enExample) |
| AU (1) | AU2004266057A1 (enExample) |
| BR (1) | BRPI0413587A (enExample) |
| CA (1) | CA2536275A1 (enExample) |
| IS (1) | IS8277A (enExample) |
| MX (1) | MXPA06002002A (enExample) |
| NO (1) | NO20061167L (enExample) |
| WO (1) | WO2005018676A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457738C (zh) * | 2001-12-20 | 2009-02-04 | H·隆德贝克有限公司 | 芳氧基苯基和芳硫基苯基衍生物 |
| WO2008100727A2 (en) * | 2007-02-14 | 2008-08-21 | The Trustees Of Columbia University In The City Of New York | High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders |
| CN101338337B (zh) * | 2007-07-04 | 2011-11-02 | 北京华安佛医药研究中心有限公司 | 多态性位点基因型预测抑郁症及药效的用途、方法和试剂盒 |
| EP2380595A1 (en) | 2010-04-19 | 2011-10-26 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| CN102949364A (zh) * | 2011-08-30 | 2013-03-06 | 天津药物研究院 | 一种含有效成分盐酸维拉佐酮的缓释片 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL124536A (en) * | 1995-12-07 | 2001-03-19 | Daniel C Javitt | Pharmaceutical compositions containing a glycine uptake antagonist |
| US6361957B1 (en) * | 1999-08-03 | 2002-03-26 | Glytech, Inc. | Assay for D-serine transport antagonist and use for treating psychosis |
| CA2619901A1 (en) * | 1996-05-31 | 1997-12-04 | Allelix Neuroscience Inc. | Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| GB2336534A (en) * | 1998-04-24 | 1999-10-27 | Alec James Coppen | Anti-depressant - Folic Acid Combination |
| DOP2001000189A (es) * | 2000-06-30 | 2002-03-30 | Pfizer Prod Inc | Benzofenonas y sulfonas como inhibidores de la captación de glicina |
| CZ2003396A3 (cs) * | 2000-07-21 | 2003-05-14 | H. Lundbeck A/S | Inhibitory transportu glycinu |
| CN100457738C (zh) * | 2001-12-20 | 2009-02-04 | H·隆德贝克有限公司 | 芳氧基苯基和芳硫基苯基衍生物 |
| EP1545552B1 (en) * | 2002-06-20 | 2007-03-28 | H. Lundbeck A/S | Combination therapy wherein a serotonin reuptake inhibitor is used |
| AU2004251636B2 (en) * | 2003-05-27 | 2006-11-09 | Merz Pharma Gmbh & Co. Kgaa | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
-
2004
- 2004-08-18 WO PCT/DK2004/000547 patent/WO2005018676A1/en not_active Ceased
- 2004-08-18 EP EP04739042A patent/EP1660130A1/en not_active Withdrawn
- 2004-08-18 KR KR1020067003210A patent/KR20060066729A/ko not_active Withdrawn
- 2004-08-18 US US10/568,133 patent/US20060223857A1/en not_active Abandoned
- 2004-08-18 CN CNA2004800304533A patent/CN1867358A/zh active Pending
- 2004-08-18 AU AU2004266057A patent/AU2004266057A1/en not_active Abandoned
- 2004-08-18 CA CA002536275A patent/CA2536275A1/en not_active Abandoned
- 2004-08-18 BR BRPI0413587-3A patent/BRPI0413587A/pt not_active IP Right Cessation
- 2004-08-18 JP JP2006523530A patent/JP2007502785A/ja not_active Withdrawn
- 2004-08-18 MX MXPA06002002A patent/MXPA06002002A/es not_active Application Discontinuation
-
2006
- 2006-01-31 IS IS8277A patent/IS8277A/is unknown
- 2006-03-13 NO NO20061167A patent/NO20061167L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2536275A1 (en) | 2005-03-03 |
| MXPA06002002A (es) | 2006-05-17 |
| WO2005018676A1 (en) | 2005-03-03 |
| IS8277A (is) | 2006-01-31 |
| CN1867358A (zh) | 2006-11-22 |
| BRPI0413587A (pt) | 2006-10-17 |
| EP1660130A1 (en) | 2006-05-31 |
| NO20061167L (no) | 2006-03-13 |
| AU2004266057A1 (en) | 2005-03-03 |
| JP2007502785A (ja) | 2007-02-15 |
| US20060223857A1 (en) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007513052A (ja) | セロトニン再取り込み阻害剤およびアゴメラチンの併用。 | |
| EP1545552B1 (en) | Combination therapy wherein a serotonin reuptake inhibitor is used | |
| KR20060066729A (ko) | 우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합 | |
| KR20060124639A (ko) | 세로토닌 재흡수 억제제 및 히스타민 ３ 수용체안타고니스트, 역 아고니스트 또는 부분 아고니스트의 조합 | |
| JP2007513896A (ja) | セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用 | |
| JP2007513896A6 (ja) | セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用 | |
| JP2007504181A (ja) | セロトニン再取り込み阻害剤およびロキサピンの併用 | |
| KR20060072127A (ko) | 세로토닌 재흡수 억제제 및 록사핀의 조합 | |
| US20080167290A1 (en) | Combination of a Serotonin Reuptake Inhibitor and Amoxapine | |
| KR20060072126A (ko) | 세로토닌 재흡수 억제제 및 아목사핀의 조합 | |
| ZA200601084B (en) | The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | |
| MXPA06005127A (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
| CA2579520A1 (en) | Combination therapy wherein a serotonin reuptake inhibitor is used | |
| ZA200409278B (en) | Combination therapy wherein a serotonin reuptake inhibitor is used |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20060216 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |